alpha-Galactosylceramide [alpha-Gal-Cer; KRN7000]
AG-CN2-0013
Overview
- SupplierAdipoGen Life Sciences
- Product Namealpha-Galactosylceramide [alpha-Gal-Cer; KRN7000] [158021-47-7]
- Delivery Days Customer10
- CAS Number158021-47-7
- CertificationResearch Use Only
- Estimated Purity>96%
- Molecular FormulaC50H99NO9
- Molecular Weight858.3
- Scientific DescriptionChemical. CAS: 158021-47-7. Formula: C50H99NO9. MW: 858.3. Synthetic. Originally isolated from the marine sponge Angelas mauritianus. Immunostimulant. Potent stimulator of natural killer T (NKT) cells. Specific ligand of the lipid-binding MHC class I-like protein CD1d in human and mouse NKT cells. Protects against LPS-induced shock. Potent antitumor compound. - Immunostimulant [1, 2, 3]. Potent stimulator of natural killer T (NKT) cells [4, 5]. Specific ligand of the lipid-binding MHC class I-like protein CD1d in human and mouse NKT cells [5]. Protects against LPS-induced shock [7]. Potent antitumor compound [2, 6, 8].
- SMILES[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].[H].CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](COC1OC(CO)C(O)C(O)C1O)NC(=O)CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#C
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200
References
- Synthesis of alpha-, beta-monoglycosylceramides and four diastereomers of an alpha-galactosylceramide: M. Morita, et al.; Bioorg. Med. Chem. Lett. 5, 699 (1995)
- Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties: K. Motoki, et al.; Biol. Pharm. Bull. 18, 1487 (1995)
- Immunostimulatory activities of monoglycosylated alpha-D-pyranosylceramides: A. Uchimura, et al.; Bioorg. Med. Chem. 5, 2245 (1997)
- Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein: Fujii S, et al.; J. Exp. Med. 198, 267 (2003)
- Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides: K.O. Yu, et al.; PNAS 102, 3383 (2005)
- A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer: A. Ishikawa, et al.; Clin. Cancer Res. 11, 1910 (2005)
- Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock: G. Sireci, et al.; J. Leukoc. Biol. 81, 607 (2007)
- alpha-Galactosylceramide activates antitumor immunity against liver tumor: T. Tatsumi, et al.; Hepatol. Res. 41, 160 (2011)